Report Interpretation

Overview

This event-driven note assesses Hengrui's license-out of HRS-1596 to Novo and its implications for the company's broader obesity and metabolic-disease franchise. Goldman Sachs sees the transaction as external validation of a differentiated pipeline and retains its Buy rating.

Core views

Hengrui has granted Novo exclusive ex-China rights to HRS-1596, a Phase I-ready oral GLP-1/GIP peptide designed for once-weekly administration. The consideration comprises US$300mn upfront, up to US$2.3bn in development, regulatory and commercial milestones, plus royalties on future sales. HRS-1596 has received Chinese IND approval for obesity and type 2 diabetes studies; Hengrui plans to begin China Phase I trials in 2026 and expects preliminary data in 2027. Goldman Sachs stresses that the asset remains early stage, but interprets Novo's upfront payment as evidence of strategic interest in differentiated oral incretin therapies and as validation of Hengrui's global metabolic franchise. The institution argues that the deal also supports Hengrui's wider strategy in obesity and metabolic disease. Although Hengrui entered GLP-1 later than global peers, it has built a pipeline intended to differentiate through more than weight-loss efficacy. Its approaches include GLP-1/GIP and other multi-target agonists, oral and long-acting formats intended to improve convenience, and novel INHBE and amylin-based approaches aimed at preserving muscle mass and generating broader metabolic benefits. HRS-9531 is identified as a central strategic asset: Phase II data showed 12.1% weight loss at week 26, 9.8% placebo-adjusted, with a reported vomiting rate of 11.4%. Goldman Sachs places the Novo transaction within Hengrui's increasingly diversified overseas business-development effort, which it believes now extends beyond oncology. The firm describes Hengrui as transitioning from a former “generics + innovation” model toward innovative drugs. It notes that Hengrui has launched nine drugs with sales above Rmb1bn in recent years, including four innovative drugs, and expects future growth drivers to include HER2 ADC, CDK4/6, androgen-receptor antagonist, PI3K inhibitor, obesity and autoimmune assets. The report believes the bulk of the impact from volume-based-procurement price cuts was reflected and reset to a lower base in 2022. Goldman Sachs maintains a Buy rating and a 12-month Rmb73.86 target price versus Rmb45.62 at the 29 September 2026 close, implying 61.9% upside. Its valuation combines a Rmb39.3bn long-term exit valuation for the generics business, based on a five-year exit P/E of 10x, with a Rmb390.7bn risk-adjusted DCF valuation for innovative drugs, using a 9.0% WACC and 3% terminal growth rate. The report's central valuation argument is that the current valuation largely reflects Hengrui's China prospects, while progress in overseas commercialization and licensing could provide further upside.

Analysis framework

Goldman Sachs begins with the commercial terms and clinical status of the Novo license agreement, then assesses how the deal validates Hengrui's obesity strategy and compares its modalities with the broader long-acting GLP-1 landscape. It connects the event to Hengrui's innovation-led growth and overseas licensing record, and values the company through a generics exit P/E approach plus a risk-adjusted DCF for innovative drugs.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Risk-adjusted DCF valuation for innovative drugs

  The report values Hengrui's innovative-drug business at Rmb390.7bn using a 9.0% WACC and 3% terminal growth rate, adjusting for the risks inherent in drug development.

• Valuation methodsP/E and PEG Valuation

  Five-year exit P/E valuation for the generics business

  Goldman Sachs applies a 10x long-term exit P/E to derive a Rmb39.3bn valuation for Hengrui's generics business.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  Pipeline and licensing-based assessment of obesity-drug differentiation

  The report evaluates how Hengrui's drug mechanisms, formats, clinical development and overseas licensing translate into strategic value for its metabolic franchise.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Hengrui Medicine (600276.SS)

  Primary covered company; the Novo agreement is presented as validation of its obesity pipeline and overseas business-development strategy.

  Strengths

  Diversified innovative-drug pipeline, established sales force, nine recently launched drugs with sales above Rmb1bn, and expanding overseas licensing activity.

  Weaknesses

  Entered the GLP-1 field later than global peers; HRS-1596 remains at an early clinical stage.

  Comparison

  The report positions Hengrui's differentiated oral, long-acting and multi-target approaches against a broader global long-acting GLP-1 competitive landscape.

  Risks

  Slower innovative-drug ramp after NRDL listing, late-stage R&D failure, higher global-expansion costs, price cuts and weaker-than-expected license-out progress.

• Novo

  Counterparty obtaining exclusive ex-China rights to HRS-1596.

  Strengths

  Described by the report as a global leader in obesity.

  Comparison

  Its commitment is used as third-party validation of differentiated oral incretin therapies.

Key data

• HRS-1596 upfront paymentUS$300mnNovo's upfront payment for exclusive ex-China rights.
• HRS-1596 potential milestonesUp to US$2.3bnDevelopment, regulatory and commercial milestones, in addition to royalties.
• HRS-9531 weight loss12.1% at week 269.8% placebo-adjusted in reported Phase II data.
• HRS-9531 vomiting rate11.4%Reported as favorable tolerability.
• 12-month target priceRmb73.86Versus Rmb45.62 closing price as of 29 September 2026; implied upside of 61.9%.
• Innovative-drug valuationRmb390.7bnRisk-adjusted DCF using 9.0% WACC and 3% terminal growth.

Impact & implications

Goldman Sachs believes Novo's commitment strengthens investor confidence in Hengrui's cardiometabolic pipeline and demonstrates growing overseas value creation beyond oncology. The report argues that such progress could provide upside because the current valuation largely reflects Hengrui's China prospects.

Risks

• Innovative drugs may ramp more slowly than expected after NRDL listing.
• Key late-stage R&D programs may fail.
• R&D and administrative expenses for global expansion may exceed expectations.
• Price cuts for generics and innovative drugs may be greater than expected.
• License-out and broader overseas expansion progress may fall below expectations.

What to watch

• The start of HRS-1596 China Phase I trials in 2026 and preliminary data expected in 2027.
• Further progress in Hengrui's obesity and metabolic-disease pipeline, including oral, long-acting and multi-target programs.
• Execution of overseas licensing and commercialization initiatives beyond oncology.
• The pace of innovative-drug launches and commercialization following NRDL listing.